Positive TAPUR data in advanced CRC presented at GI Cancer Symposium

The 2020 Gastrointestinal (GI) Cancers Symposium presented the latest data in the field, including findings from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

TAPUR, the first clinical trial conducted by the American Society of Clinical Oncology (ASCO), aims to identify additional uses for targeted therapies that are already FDA approved. The Phase II multibasket trial utilizes a biomarker-based approach that is hoped to open new avenues for precision medicine.1,2

New data from three advanced colorectal cancer (CRC) cohorts in TAPUR were presented at the symposium: cobimetinib and vemurafenib in BRAF V600E-mutated disease; pertuzumab and trastuzumab in HER2-positive patients; and pembrolizumab in those with high tumor mutation burden (TMB).3-5

  1. According to Klute K et al., cobimetinib plus vemurafenib showed anti-tumor activity in advanced CRC patients with BRAF V600E mutations.3 This combination is already approved for metastatic melanoma with a BRAF V600E or V600K mutation.
  2. Data by Gupta R et al. demonstrated that the combination of pertuzumab and trastuzumab showed activity and was well tolerated in heavily pre-treated CRC with HER2 amplification. The authors mention that additional analyses by RAS mutation status are underway.4
  3. Finally, Meiri E et al. presented the finding that anti-tumor activity was observed with pembrolizumab monotherapy n heavily pre-treated CRC with high TMB.5

While these data were positive, the authors highlight that further study is warranted to confirm the observed efficacy. Nonetheless, these results illustrate the power of biomarker-based personalized treated in CRC and further results are eagerly awaited.

Written by Cally Cameron Smith

References

  1. Dailynews.ascopubs.org [Internet]. USA. TAPUR Study Illustrates the Power of Personalized Biomarker-Based Treatment in Colorectal Cancer. Available from: https://dailynews.ascopubs.org/do/10.1200/ADN.20.200012/full/?et_cid=41124810&et_rid=2118121508&linkid=ASCO+Daily+News. [Accessed 28 Jan 2020].
  2. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02693535. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR). Available from: https://clinicaltrials.gov/ct2/show/NCT02693535. [Accessed 28 Jan 2020].
  3. Klute K, Garrett-Mayer E, Halabi S et al. Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study. In: American Society of Clinical Oncology 2020 Gastrointestinal Cancers Symposium; January 23-25, 2020; San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 122).
  4. Gupta R, Garrett-Mayer E, Halabi S et al. Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study. In: American Society of Clinical Oncology 2020 Gastrointestinal Cancers Symposium; January 23-25, 2020; San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 132).
  5.  Meiri E, Garrett-Mayer E, Halabi S et al. Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. In: American Society of Clinical Oncology 2020 Gastrointestinal Cancers Symposium; January 23-25, 2020; San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 133).